AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00002772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00002772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01867125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
Study NCT01867125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
Study NCT01867125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Study NCT01867125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Study NCT04380935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma of recovered COVID-19 patients (donor)
Study NCT04380935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: According to national or hospital guidelines COVID-19 Management Protocol
Study NCT04380935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: According to national or hospital guidelines COVID-19 Management Protocol
Study NCT00813384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 208
Description: AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
Study NCT02499211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention stores
Description: In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.~Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.~Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them.
Study NCT01396135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
Study NCT01396135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
Study NCT01396135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
Study NCT01396135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo given as a matching number of oral tablets
Study NCT01396135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-601,927
Description: Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
Study NCT01396135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple doses of placebo given as a matching number of oral tablets
Study NCT02840123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells
Study NCT03191318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS pathway
Description: ERAS pathway after laparoscopic sleeve gastrectomy
Study NCT03191318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pathway
Description: Standard pathway after laparoscopic sleeve gastrectomy
Study NCT02982252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoPILOT
Description: Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
Study NCT03181880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium bromide/formoterol fumarate combination
Description: Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment.
Study NCT03181880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Brochodilators
Study NCT04659980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hilotherapy
Description: continuous cooling of hands and feet at a constant temperature
Study NCT04659980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: frozen gloves
Description: cooling of hands and feet using frozen gloves
Study NCT04394949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center for Independent Living SEEKS Team
Description: Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
Study NCT04394949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Consumers will get same CIL services they would get if they were not enrolled in the study.
Study NCT00764660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900435
Description: tablets
Study NCT00764660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study NCT03053037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: final apical size instrumentation
Description: root canal instrumentation to two different final preparation sizes
Study NCT01866462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NM504
Description: NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
Study NCT03524417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Equine rabies immunoglobulin injection on day 7
Description: The patients with WHO category III rabies exposure, who have received first dose of rabies vaccination a week before and have not received rabies immunoglobulin were enrolled. Blood for Rabies neutralizing antibody titers (RNab) would be examined on day 0. On the same day, Equine rabies immunoglobulin (ERIG) at the dosage of 40 IU/kg would be injected into and around the wound as much as possible and the rest would be injected intramuscularly at the site distance from rabies vaccine. Then blood for RNab would be serially examined on day 7, 14, 90, 365.
Study NCT00203619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless capsule endoscopy
Description: wire less capsule endoscopy
Study NCT00203619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard diagnostic evaluation as decided by treating physician
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT00885404 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lower chloride fluids (Hartmann's solution and Plasmalyte®)
Description: Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
Study NCT04674358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
Study NCT04674358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Opthalmic Solution
Description: Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
Study NCT03774186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop therapy
Description: Hybrid closed-loop therapy with a proportional integral derivative (PID) algorithm
Study NCT03774186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-augmented pump therapy
Description: Insulin pump + non-communicating CGM
Study NCT05414396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Attend EML program sessions
Study NCT05414396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04192994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Antibiotic Injection
Description: Intravitreal Antibiotic Injection
Study NCT04192994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy
Description: Pars Plana Vitrectomy
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Part of standard chemotherapy
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Part of standard chemotherapy
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6-Mercaptopurine
Description: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG asparaginase
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib\* (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PEG asparaginase
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib\* (Randomization R2)
Study NCT04014660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2
Study NCT04014660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo supplement consists of corn starch only.
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Part of standard chemotherapy
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Part of standard chemotherapy
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Part of standard chemotherapy
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thioguanine
Description: Part of standard chemotherapy
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study NCT04043494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
Study NCT03231813 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sodium lauryl sulphate induced irritation
Description: Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.
Study NCT03231813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate induced irritation
Description: Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.
Study NCT03231813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient, moisturizing cream
Description: Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
Study NCT03231813 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Emollient, moisturizing cream
Description: Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
Study NCT05214690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-T2
Description: pelubiprofen 25mg
Study NCT05214690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-1
Description: pelubiprofen 30mg (PELUBI tab.)
Study NCT05358054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement lateral Glides and Conventional Physiotherapy
Description: (The Mobilization with movement technique is(lateral glide) applied to the patient by a physiotherapist to patients at supine level position.~First we identify pain free region each patients. The lateral humerus above the condyle of elbow joint are fixed by therapist. Then therapist ask to patients perform the active movement ten times. The same procedure repeats number of 3 sets, 10 number of repetition. The rest of interval fifteen to twenty seconds with in the sets Grip strength (pain Free Strength ) was evaluated in kilogram using a dynamometer. The measurements using dynamometer patients posture is erect sit position , the elbow at 90 degree flexion , shoulder would be abducted , rest of joint forearm and wrist in neutral during measurements.~conventional therapy list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching
Study NCT05358054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercises and Conventional Physiotherapy
Description: 4 STEPS Progressive resistive EXERCISES have a 4 step to application Step 1 Clenching fist strongly, resisted wrist Flexion, Extension, wrist rotation with a stick) Step 2 The therapeutic band exercised performed at wrist Flexion(WF), Wrist Extension(WE), Wrist Ulnar Deviation(WED) , and Wrist Radial Deviation(WRD).Step 3 Patient asked to perform combined wrist rotatory movements using e.g. table top as a support. Step 4 Soft ball compressing exercises, Transferring buttons from cup into another, Twisting a towel into the roll, Hand Rotating both directions at table AND CONVENTIONAL PHYSIOTHERAPY and list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching
Study NCT01276756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Description: Pegylated interferon 160ug once weekly 48 weeks
Study NCT01276756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Pegylated interferon 160ug once weekly 48 weeks